Having joined Atos as a Digital Transformation Consultant in 2019, Kaysee quickly took leadership in demanding roles, and has become a trusted partner to clients across the public and private sector.
Within a year of joining the company, Kaysee played a key role in some of Atos’ most significant innovation workshops, namely StratHacks, and recently partnered with a leading utilities company to create a strategy for decarbonisation. Following this, Kaysee led the Business Change workstream on a large transformation programme, where she created a strategy for continuous engagement with Microsoft’s evergreen IT model and designed a Ways of Working campaign. She has since worked as the lead Business Analyst on a global Digital Workplace programme, where she demonstrated her in-depth knowledge of Microsoft 365 technologies and natural ability to understand user requirements.
Outside of client work, Kaysee goes above and beyond to champion digital technology through her extra-curricular activities. She is currently the engagement lead for Atos’ Green Network, who aim to leverage technology to create greener products and services for clients. She also leads Atos’ fundraising effort as part of the Million Makers programme, where she has created a number of innovative, digital initiatives to raise money for The Prince’s Trust. Kaysee invests her time in developing Atos’ internal offerings including Digital Strategy and Innovation, and recently evaluated the organisations’ communications strategy following the COVID-19 pandemic. She also educates colleagues about emerging technologies and significant client engagements through her organisation of regular Knowledge Shares.
In her free time, Kaysee volunteers as an NHS Digital Champion, where she provides free training sessions to improve awareness of NHS digital applications, with the goal of reducing the demand on GP surgeries. She is also a member of the NHS Volunteer Responders programme, where she supports vulnerable people across England who are at the most risk from COVID-19.
